Two questions from the article: Unless the 36 patient number is significantly out of date the enrollment curve to hit the Q2 2012 target needs to be steep. I guess that's not a question but one can be inferred.
Why is frozen ICT-107 effective when it is largely agreed that frozen Provenge (usually referred to as Frovenge) is thought to be significantly less effective than "fresh" Provenge.
According to recent SEC filings the enrollment for current trial was going at a really good pace with over 86 patients entered. With recent announcement of Wake Forest participating now and with over 20 centers involved I would guess that they are around the 100+ mark
IMUC has patents protecting both the manufacturing process and method of delivery of ICT-107, as well as the 6 antigens that compose the compound.
IMUC's method of being able to use a single draw and create a personalized treatment for 3 years worth of use gives them a tremendous advantage in cost, which for us shareholders will create better profit margins. And it will alleviate some of the burden that patients have to deal with since it will lessen the number of lab visits and blood draws.